10/20/2014

Aachen, Germany, October 20th 2014 Sascha Becker will be appointed to the Executive Board of the pharmaceutical company Grünenthal and take over the finance unit as Group Chief Financial Officer in the first quarter of 2015. Since 2003, Sascha Becker (43) has been working for Merck and is currently CFO of the biopharmaceutical division Merck Serono with an annual turnover of 6.3 billion Euros and 10.000 employees. He is succeeding Stefan Genten, who decided to look for new challenges outside of Grünenthal and thus did not prolong his contract that will terminate at the end of 2014.

published:  20 Oct 2014

About Grünenthal

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. The research and development costs amounted to a preliminary of about 26 percent of revenues in 2012. Grünenthal′s research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies. Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries and today approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2012, Grünenthal achieved preliminary revenues of € 973 mn.

More information: www.grunenthal.com

• Sascha Becker will join Grünenthal Group as new CFO (pdf, 73.1 KB)